62136-38-3

Usage

Structure

Hydrazone derivative of 1,2-Cyclopentanedione
It is formed by the reaction of 1,2-Cyclopentanedione with phenylhydrazine, resulting in a hydrazone functional group.

Physical state

Yellow solid
The compound appears as a yellow-colored solid at room temperature.

Melting point

208-210°C
The temperature range at which the compound transitions from a solid to a liquid state.

Solubility

Insoluble in water, soluble in organic solvents
The compound does not dissolve in water but dissolves in organic solvents like ethanol and ether.

Applications

Reactant in organic synthesis
It is used as a starting material or intermediate in the synthesis of various organic compounds.

Use in analytical chemistry

Detection and determination of functional groups
The compound serves as a reagent for identifying and quantifying specific functional groups in organic molecules.

Stability

Stable under normal conditions
The compound is generally stable when stored and handled properly, avoiding extreme temperatures or reactive substances.

Upstream product

• 100-34-5 benzene diazonium chloride 
• 611-10-9 2-ethoxycarbonyl-1-cyclopentanone 
• 1192-54-7 2-formylcyclopentanone 
• 930-91-6 2-hydroxymethylenecyclopentanone 
• 120-92-3 cyclopentanone 
• 109-94-4 formic acid ethyl ester 
• 62-53-3 aniline 

Downstream Products

• 6782-74-7 cyclopentane-1,2-dione-bis-phenylhydrazone 
• 16244-15-8 1,4-dihydrocyclopenta[b]indol-3(2H)-one 
• 869194-33-2 4-benzyl-7-fluoro-1,4-dihydrocyclopenta[b]indol-3(2H)-one 
• 869194-38-7 (3R)-4-benzyl-1,2,3,4-tetrahydrocyclopenta[b]indol-3-ol 
• 441067-91-0 2-(4'-methoxy)-benzylidineindolo[2,3-b]cyclopentan-1-one 

Relevant academic research and scientific papers

A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability

Aurora kinase inhibitors have attracted a great deal of interest as a new class of antimitotic agents. We report a novel class of Aurora inhibitors based on a pentacyclic scaffold. A prototype pentacyclic inhibitor 32 (AKI-001) derived from two early lead

Synthesis and biological activity of a novel class of pyridazine analogues as non-competitive reversible inhibitors of protein tyrosine phosphatase 1B (PTP1B).

A series of novel pyridazine analogues were prepared and the structure-activity relationship of their behavior as inhibitors of PTP1B was evaluated. Most of the analogues had potencies in the low micromolar range. The in vitro kinetics of this compound series demonstrated that they were reversible non-competitive binders. This indicates that there may exist another site in the enzyme through which enzyme activity can be inhibited, which is not a recognized interaction domain. Some of the analogues exhibited high selectivity for other PTPases, for example, compound 12 mp showed 20-fold selectivity for PTP1B (IC50=5.6 microM) versus both TCPTP and LAR (>100 microM, respectively). In contrast to many tyrosine phosphatase mimetic inhibitors, this compound class lacks negative charge and thus showed high permeability across cell membranes. Selective analogues in the series were analyzed in an in vitro cellular assay, which showed increased insulin-stimulated insulin receptor phosphorylation.

Tetracyclic compounds from cyclopent[b]indoles. Synthesis of isoxazolo[3′,4′:5,4]cyclopent[b]indoles

Cyclopentan-1′,2′-dione-1′-arylhydrazones 3 obtained from the Japp-Klingemann reaction of diazotised aniline derivatives 1 and 2-hydroxymethylenecyclopentanone 2 on acid catalysed cyclization afforded cyclopent[b]indoles 4. These on mixed aldol condensati